Source: United States House of Representatives – Representative Judy Chu (CA2-27)
WASHINGTON, D.C. — Today, Representatives Judy Chu (CA-28), Kathy Castor (FL-14), Summer Lee (PA-12), and Chris Pappas (NH-01) introduced the Drug Deal Disclosure Act, legislation that would require the Trump Administration to publicly disclose its prescription drug pricing agreements with pharmaceutical manufacturers and subject those agreements to independent review to determine whether they are actually lowering costs for patients and taxpayers.
As Americans continue to struggle with the high cost of prescription drugs, the Trump Administration has repeatedly claimed that a series of agreements negotiated with pharmaceutical companies will lower costs for patients. Yet despite public announcements and White House events promoting these arrangements, the Administration has refused to disclose the terms of the agreements, the concessions offered in exchange, and evidence that they will actually deliver lower prices.
“President Trump has repeatedly claimed that his Administration’s private deals with pharmaceutical companies will lower prescription drug prices for American families. If that’s true, then he should have nothing to hide,” said Rep. Chu. “Democrats didn’t ask Americans to simply trust us when we lowered prescription drug costs through the Inflation Reduction Act, we passed a law that empowered Medicare to negotiate drug prices, capped insulin at $35 a month for seniors, limited annual out-of-pocket prescription drug costs, and held drug companies accountable for unjustified price hikes. Those reforms are already delivering real savings. If President Trump wants the American people to believe his secret deals with Big Pharma will do the same, then he should release the agreements and let the facts speak for themselves.”
“Floridians and Americans deserve lower drug costs,” said Rep. Castor. “No one should have to choose between putting food on the table and paying for their lifesaving medications. After making health care out of reach for millions of Americans, the Trump Administration claims they are helping our neighbors afford prescription drugs through closed-door deals with pharmaceutical manufacturers. Americans are skeptical and deserve to know if those deals are truly lowering costs, or if they are another false promise. I was proud to work with my colleagues in the Congress to actually lower drug costs through Medicare negotiation, caps on insulin, no-cost vaccines and out-of-pocket limits. Our neighbors have waited long enough for fair prices for important medications, and I am committed to doing that in a transparent manner.”
“No one in Western Pennsylvania should have to ration medicine or walk away from the pharmacy counter because Big Pharma and the Trump Administration are cutting deals behind closed doors,” said Rep. Lee. “More than one in four Pennsylvanians have already been forced to skip doses, cut pills in half, or leave prescriptions unfilled simply because of cost. People paying the price deserve to know who these agreements are really serving, and this bill would force the Administration to release these secret agreements and require independent analysis of whether they actually lower costs for patients and taxpayers. I’m proud to co-lead this bill and help build a healthcare system that works for the people, not billion-dollar corporations.”
“Deals made by the White House are the business of the American people. President Trump claims to have made secret agreements with Big Pharma CEOs under the pretense of lowering prescription drug prices but these savings have yet to appear. The American people deserve answers and this legislation will bring them to light,” said Rep. Pappas. “Granite Staters are paying too much for life-saving prescription drugs and this administration and Republicans in Congress have only made health care access worse and costs higher. I remain committed to doing everything I can to improve care and lower costs, and I will not stand for shady deals and false promises made by the administration.”
The Drug Deal Disclosure Act would require the Department of Health and Human Services (HHS) to publicly disclose records, communications, agreements, and related materials concerning drug pricing agreements and other arrangements negotiated between the Trump Administration and pharmaceutical manufacturers. The bill would also require reporting to Congress and direct the Congressional Budget Office (CBO) and Government Accountability Office (GAO) to conduct an independent analysis of the agreements’ economic and budgetary impacts.
Specifically, the legislation would:
• Require HHS to publicly disclose agreements, communications, records, and related materials concerning covered agreements between the Trump Administration and pharmaceutical manufacturers;
• Require disclosure of agreements involving Most-Favored-Nation pricing commitments, TrumpRx participation, tariff exemptions, domestic investment commitments, Strategic National Stockpile agreements, Priority Review Vouchers, and other related arrangements;
• Require HHS to report to Congress on all documents and information released or withheld, including the basis for any redactions; and
• Direct CBO and GAO to publish an independent assessment of the agreements’ impacts on patients, taxpayers, prescription drug costs, Medicare, Medicaid, competition, and federal spending.
The Drug Deal Disclosure Act is the House companion to legislation introduced in the Senate by Senate Finance Committee Ranking Member Ron Wyden and Senate Democrats.
This legislation is cosponsored by Reps. Don Beyer (VA-08), Andre Carson (IN-07), Yvette Clarke (NY-09), Suzan DelBene (WA-01), Maxine Dexter (OR-03), Lloyd Doggett (TX-37), Dwight Evans (PA-03), Maggie Goodlander (NH-02), Doris Matsui (CA-07), Betty McCollum (MN-04), Kweisi Mfume (MD-07), Gwen Moore (WI-04), Eleanor Holmes Norton (DC-AL), Jimmy Panetta (CA-19), Deborah Ross (NC-02), Jan Schakowsky (IL-09), Brad Schneider (IL-10), Mark Takano (CA-39), Rashida Tlaib (MI-12), and Nikema Williams (GA-05).